CNQ · BETR.CN
BetterLife Pharma Inc.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
Loading market information…
OTC · BIXT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 06:02 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bioxytran, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bioxytran, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
$0.01+$0.00 (+6.67%)
ProText Mobility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
CA$0.04CA$0.00 (0.0%)
Glow Lifetech Corp.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
CA$0.04CA$0.00 (0.0%)
Kane Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.0% below the high.
$0.09$0.00 (0.0%)
BioVaxys Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.73% below the high.
$0.14$0.00 (0.0%)
Mosaic ImmunoEngineering Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.61% below the high.
$0.01$0.00 (0.0%)
MYND Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
$0.00$0.00 (0.0%)
Theralink Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
